ODM derived from

  1. 12/9/13 12/9/13 - Martin Dugas
  2. 4/15/14 4/15/14 - Julian Varghese
  3. 9/20/21 9/20/21 -
Uploaded on:

September 20, 2021

To request one please log in.
License :
Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00641056 Type 2 Diabetes Mellitus


  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
age at least 18 Years
Has type 2 diabetes and at least 18 years of age at screening.
Hemoglobin A1c (HbA1c) of 7.1% to 11.0%, inclusive, at screening.
Body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.
Have a history of stable body weight (not varying by >5% for at least 3 months prior to screening).
Have been treated with metformin(Met) for at least 3 months and have been taking a stable dose for at least 8 weeks prior to screening OR
Have been treated with metformin(Met) for at least 3 months and have been taking a stable dose for at least 8 weeks prior to screening and have been treated with SU for at least 3 months and have been taking a stable dose of at least an optimally effective dose of brand of SU for 8 weeks prior to screening.
Exclusion Criteria
Have had a clinically significant history of cardiac disease or presence of active cardiac disease within the year prior to inclusion in the study, including myocardial infarction, clinically significant arrhythmia, unstable angina, moderate to severe congestive heart failure, coronary artery bypass surgery, or angioplasty. or is expected to require coronary artery bypass surgery or angioplasty during the course of the study.
Have clinical signs or symptoms of liver disease, acute or chronic hepatitis.
Have a history of renal transplantation or are currently receiving renal dialysis.
Have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
Have had > 3 episodes of major hypoglycemia within 6 months prior to screening.
Have any contraindication for the oral antidiabetic agent which they use.
Have a known allergy or hypersensitivity to insulin glargine, exenatide once weekly, or excipients contained in these agents.
Are known to have active proliferative retinopathy.
Have been treated with drugs that promote weight loss (e.g., Xenical [orlistat], Meridia [sibutramine], Acomplia [rimonabant], Acutrim [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening.
Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to screening:
Insulin, regular insulin
Thiazolidinediones (e.g., Actos [pioglitazone] or Avandia [rosiglitazone])
Alpha-glucosidase inhibitors (e.g., Glyset [miglitol] or Precose [acarbose])
Meglitinides (e.g., Prandin [repaglinide] or Starlix [nateglinide]).
Byetta (exenatide BID formulation)
Dipeptidyl peptidase (DPP)-4 inhibitors (e.g., Januvia [sitagliptin], Galvus [vildagliptin])
Symlin, Pramlintide Acetate
Organ Transplantation, Organ Transplant
Have donated blood within 30 days of screening.
Have previously completed or withdrawn from this study or any other study investigating exenatide once weekly.
Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Are currently enrolled in any other clinical study.

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial